TelmisattanAngiotensin II receptor antagonist CAS# 144701-48-4 |
- Perindopril Erbumine
Catalog No.:BCC3586
CAS No.:107133-36-8
- Losartan Potassium (DuP 753)
Catalog No.:BCC1080
CAS No.:124750-99-8
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Rosuvastatin Calcium
Catalog No.:BCC3853
CAS No.:147098-20-2
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 144701-48-4 | SDF | Download SDF |
| PubChem ID | 65999 | Appearance | Powder |
| Formula | C33H30N4O2 | M.Wt | 514.62 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | BIBR 277 | ||
| Solubility | DMSO : 6.67 mg/mL (12.96 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid | ||
| SMILES | CCCC1=NC2=C(C=C(C=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C5=NC6=CC=CC=C6N5C)C | ||
| Standard InChIKey | RMMXLENWKUUMAY-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Antagonist of the angiotensin II type 1 receptor (AT1) (Ki = 3.7 nM). Exhibits antihypertensive activity in a renin-dependent model of hypertension. Partial agonist of PPARγ receptors; shown to improve insulin sensitivity in rodents receiving high fat diets. |
Telmisattan Dilution Calculator
Telmisattan Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9432 mL | 9.7159 mL | 19.4318 mL | 38.8636 mL | 48.5795 mL |
| 5 mM | 0.3886 mL | 1.9432 mL | 3.8864 mL | 7.7727 mL | 9.7159 mL |
| 10 mM | 0.1943 mL | 0.9716 mL | 1.9432 mL | 3.8864 mL | 4.858 mL |
| 50 mM | 0.0389 mL | 0.1943 mL | 0.3886 mL | 0.7773 mL | 0.9716 mL |
| 100 mM | 0.0194 mL | 0.0972 mL | 0.1943 mL | 0.3886 mL | 0.4858 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Telmisartan (INN) is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. It is marketed under the trade name Micardis (by Boehringer Ingelheim), among others.
- Fmoc-D-Cha-OH
Catalog No.:BCC3161
CAS No.:144701-25-7
- Hispidulin
Catalog No.:BCN6250
CAS No.:1447-88-7
- Olmesartan medoxomil
Catalog No.:BCC2143
CAS No.:144689-63-4
- Olmesartan
Catalog No.:BCC1819
CAS No.:144689-24-7
- (+)-Lyoniresinol
Catalog No.:BCN6248
CAS No.:14464-90-5
- 22-Hydroxy-3-oxoolean-12-en-29-oic acid
Catalog No.:BCN1565
CAS No.:144629-84-5
- GR 113808
Catalog No.:BCC7019
CAS No.:144625-51-4
- CPI-203
Catalog No.:BCC4099
CAS No.:1446144-04-2
- Isomahanine
Catalog No.:BCN3177
CAS No.:144606-95-1
- Schisanlignone D
Catalog No.:BCN3630
CAS No.:144606-84-8
- Schisanlignone C
Catalog No.:BCN3629
CAS No.:144606-83-7
- IRL-1038
Catalog No.:BCC5730
CAS No.:144602-02-8
- Telmisartan tert-butyl ester
Catalog No.:BCC9161
CAS No.:144702-26-1
- 4F 4PP oxalate
Catalog No.:BCC6678
CAS No.:144734-36-1
- 2-4-Hydroxy-3-methoxyphenyl-7-methoxy-5-benzofuranpropanol
Catalog No.:BCN1564
CAS No.:144735-57-9
- Cyclo(Phe-Val)
Catalog No.:BCN2419
CAS No.:14474-71-6
- Cyclo(Ala-Phe)
Catalog No.:BCN2411
CAS No.:14474-78-3
- Clopidogrel Related Compound B
Catalog No.:BCN2688
CAS No.:144750-52-7
- Brachynoside heptaacetate
Catalog No.:BCN6249
CAS No.:144765-80-0
- L-703,664 succinate
Catalog No.:BCC7437
CAS No.:144776-01-2
- 5-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Catalog No.:BCC8720
CAS No.:144809-28-9
- Deflazacort
Catalog No.:BCC8928
CAS No.:14484-47-0
- Alpiniaterpene A
Catalog No.:BCN7085
CAS No.:1448667-05-7
- Garjasmin
Catalog No.:BCN6251
CAS No.:144868-43-9
Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.[Pubmed:19008714]
J Hypertens. 2008 Dec;26(12):2361-73.
OBJECTIVES: We investigated the effects of treatment with the angiotensin II type 1 receptor antagonist, telmisartan, on abdominal aortic aneurysm formation in normotensive rats. METHODS: Abdominal aortic aneurysm was induced by perfusion of an isolated aortic segment with elastase. Treatment with Telmisattan (0.5 mg/kg per day) or hydralazine (15 mg/kg per day) was started after surgery and continued for 14 days. Sham-operated animals and vehicle-treated animals after aneurysm induction served as controls. Aortic diameter was measured using ultrasound before aneurysm induction and on days 7 and 14 after aneurysm induction. RESULTS: On day 14, aortic diameter was increased two-fold in the vehicle-treated group compared to sham-operated animals (2.02 +/- 0.12 vs. 0.87 +/- 0.02 mm, P < 0.005, n = 8). Telmisartan treatment significantly reduced aneurysmal size (1.65 +/- 0.06 vs. 2.02 +/- 0.12 mm in vehicle, P < 0.05, n = 8), whereas treatment with hydralazine had no effect. Matrix metallopeptidase 3, cathepsin D, nuclear factor kappa B, tumour necrosis factor alpha, transforming growth factor-1 beta, as well as caspase 3, p53 and Fas ligand proteins, were significantly downregulated in aortic tissue under telmisartan compared to vehicle treatment. Serum monocyte chemoattractant protein 1 levels were also significantly decreased. Telmisartan and hydralazine reduced blood pressure to a similar extent within the observation period. CONCLUSION: The angiotensin II type 1 receptor antagonist, telmisartan, prevents abdominal aortic aneurysm progression independently of blood pressure reduction by inhibiting proteolysis, apoptosis and inflammation in aortic tissue.
An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice.[Pubmed:19770292]
J Pharmacol Exp Ther. 2009 Dec;331(3):1096-103.
Adipose tissue plays an important role in energy balance and metabolism and is the major target for insulin-sensitizing peroxisome proliferator-activated receptor (PPAR) gamma agonists. The angiotensin II type 1 receptor blocker telmisartan, a partial agonist of PPAR-gamma, has been demonstrated to improve insulin sensitivity. However, there is uncertainty about the sites of its action. Here, we demonstrate that treatment with telmisartan (3 mg/kg p.o.) for 7 weeks decreased plasma glucose levels in oral glucose and insulin tolerance tests and the index of the homeostasis model assessment of insulin resistance in A-ZIP/F-1 transgenic mice, an animal model of lipodystrophy. These effects were accompanied by decreases in circulating triglyceride and fatty acid levels. However, this treatment did not affect body weight and plasma adiponectin, leptin, and corticosterone levels. In A-ZIP/F-1 mouse liver the transcripts encoding PPAR-gamma and its downstream lipogenic genes were highly up-regulated, consistent with increased hepatic triglyceride content and lipid droplet accumulation. Telmisartan reversed these effects and also down-regulated mRNAs encoding gluconeogenic genes. Thus, the present findings are consistent with a novel mode of insulin-sensitizing action of telmisartan, involving an adipose tissue-independent pathway. Telmisartan-elicited down-regulation of hepatic expression of PPAR-gamma-regulated lipogenic genes is associated with amelioration of fatty liver.
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.[Pubmed:15007034]
Hypertension. 2004 May;43(5):993-1002.
The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure. In humans, mutations in the peroxisome proliferator-activated receptor-gamma (PPARgamma) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARgamma have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes. Here we report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARgamma; influence the expression of PPARgamma target genes involved in carbohydrate and lipid metabolism; and reduce glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet. None of the other commercially available angiotensin II receptor antagonists appeared to activate PPARgamma when tested at concentrations typically achieved in plasma with conventional oral dosing. In contrast to ordinary antihypertensive and antidiabetic agents, molecules that can simultaneously block the angiotensin II receptor and activate PPARgamma have the potential to treat both hemodynamic and biochemical features of the metabolic syndrome and could provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations.
6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships.[Pubmed:8258826]
J Med Chem. 1993 Dec 10;36(25):4040-51.
Starting from the recently reported nonpeptidic angiotensin II (AII) receptor antagonists DuP753 (1) and Exp 7711 (2), we have designed and investigated novel substituted benzimidazoles. Systemic variation of several substituents at the benzimidazole ring positions 4-7 led to the finding that substitution in position 6 with acylamino groups results in highly active AII antagonists. Compounds with 6-membered lactam or sultam substituents in position 6 of benzimidazole showed receptor activities in the low nanomolar range but were only weakly active when given orally to rats. In contrast, analogous substitution of the benzimidazole moiety with basic heterocycles resulted in potent AII antagonists which were also well absorbed after oral application. The most active compound of this series, 33 (BIBR 277), was selected as a candidate for clinical development. On the basis of molecular modeling studies a binding model of this new class of AII antagonists to the AT1 receptor is proposed.
